DE68929151T2 - Verfahren zum nachweis von aktiven domänen und aminosäureresten in polypeptiden und hormonvarianten - Google Patents

Verfahren zum nachweis von aktiven domänen und aminosäureresten in polypeptiden und hormonvarianten

Info

Publication number
DE68929151T2
DE68929151T2 DE68929151T DE68929151T DE68929151T2 DE 68929151 T2 DE68929151 T2 DE 68929151T2 DE 68929151 T DE68929151 T DE 68929151T DE 68929151 T DE68929151 T DE 68929151T DE 68929151 T2 DE68929151 T2 DE 68929151T2
Authority
DE
Germany
Prior art keywords
polypeptide
amino acid
polypeptides
substituted
acid residues
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE68929151T
Other languages
English (en)
Other versions
DE68929151D1 (de
Inventor
James A Wells
Brian C Cunningham
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of DE68929151D1 publication Critical patent/DE68929151D1/de
Publication of DE68929151T2 publication Critical patent/DE68929151T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormones [GH] (Somatotropin)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1058—Directional evolution of libraries, e.g. evolution of libraries is achieved by mutagenesis and screening or selection of mixed population of organisms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6878—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids in eptitope analysis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/61—Growth hormones [GH] (Somatotropin)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/806—Antigenic peptides or proteins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
DE68929151T 1988-10-28 1989-10-30 Verfahren zum nachweis von aktiven domänen und aminosäureresten in polypeptiden und hormonvarianten Expired - Lifetime DE68929151T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26461188A 1988-10-28 1988-10-28
US42806689A 1989-10-26 1989-10-26
PCT/US1989/004778 WO1990004788A1 (en) 1988-10-28 1989-10-30 Method for identifying active domains and amino acid residues in polypeptides and hormone variants

Publications (2)

Publication Number Publication Date
DE68929151D1 DE68929151D1 (de) 2000-03-09
DE68929151T2 true DE68929151T2 (de) 2000-07-20

Family

ID=26950658

Family Applications (1)

Application Number Title Priority Date Filing Date
DE68929151T Expired - Lifetime DE68929151T2 (de) 1988-10-28 1989-10-30 Verfahren zum nachweis von aktiven domänen und aminosäureresten in polypeptiden und hormonvarianten

Country Status (6)

Country Link
US (4) US5580723A (de)
EP (1) EP0397834B1 (de)
AT (1) ATE189526T1 (de)
CA (2) CA2345497A1 (de)
DE (1) DE68929151T2 (de)
WO (1) WO1990004788A1 (de)

Families Citing this family (144)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5688666A (en) * 1988-10-28 1997-11-18 Genentech, Inc. Growth hormone variants with altered binding properties
US5534617A (en) * 1988-10-28 1996-07-09 Genentech, Inc. Human growth hormone variants having greater affinity for human growth hormone receptor at site 1
WO1990004788A1 (en) * 1988-10-28 1990-05-03 Genentech, Inc. Method for identifying active domains and amino acid residues in polypeptides and hormone variants
US6583115B1 (en) * 1989-10-12 2003-06-24 Ohio University/Edison Biotechnology Institute Methods for treating acromegaly and giantism with growth hormone antagonists
WO1992003478A1 (en) * 1990-08-17 1992-03-05 Genentech, Inc. Metal ion mediated receptor binding of polypeptide hormones
NZ240718A (en) * 1990-11-30 1996-10-28 Bio Technology General Corp Somatotropin analogues carrying mutations in the alpha-helix-1 region
US5310882A (en) * 1990-11-30 1994-05-10 American Cyanamid Company Somatotropins with alterations in the α-helix 3 region
WO1992009690A2 (en) * 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with altered binding properties
US5780279A (en) * 1990-12-03 1998-07-14 Genentech, Inc. Method of selection of proteolytic cleavage sites by directed evolution and phagemid display
WO1992012998A1 (en) * 1991-01-17 1992-08-06 Zymogenetics, Inc. Methods for detecting glucagon antagonists
US5510459A (en) * 1991-01-17 1996-04-23 Zymogenetics, Inc. Glucagon antagonists
US6429186B1 (en) 1991-05-10 2002-08-06 Genentech, Inc. Ligand antagonists for treatment of breast cancer
JP3417558B2 (ja) 1991-05-10 2003-06-16 ジェネンテク，インコーポレイテッド 配位子作用薬および拮抗薬の選択
DE69333950T2 (de) * 1992-05-18 2006-08-17 Genentech, Inc., South San Francisco Aktivierung von Rezeptoren fähig zur Oligomerisierung durch Verwendung von fusionierten Rezeptor Liganden
US5763584A (en) * 1992-05-18 1998-06-09 Genentech, Inc. Receptor activation with hepatocyte growth factor agonists
SG54115A1 (en) 1993-04-27 1998-11-16 Gerber Scient Products Inc Thermal printing apparatus with improved power supply
IT1261787B (it) * 1993-06-23 1996-06-03 Angeletti P Ist Richerche Bio Metodologia per la selezione di superagonisti, antagonisti e super- antagonisti di ormoni del cui complesso recettoriale fa parte gp 130.
US6335319B1 (en) * 1994-11-15 2002-01-01 Metabolic Pharmaceuticals, Inc. Treatment of obesity
US6475806B1 (en) 1995-06-07 2002-11-05 Praecis Pharmaceuticals, Inc. Anchor libraries and identification of peptide binding sequences
ATE455171T1 (de) * 1995-09-21 2010-01-15 Genentech Inc Varianten des menschlichen wachstumshormons
GB9526733D0 (en) 1995-12-30 1996-02-28 Delta Biotechnology Ltd Fusion proteins
DE69712124T2 (de) * 1996-02-13 2002-12-12 Jcr Pharmaceutical Co Hormones de croissance humaines mutantes et leur utilisation
US5945296A (en) * 1996-03-29 1999-08-31 Pharmacia & Upjohn Ab Monoclonal antibody
SE9601231D0 (sv) * 1996-03-29 1996-03-29 Pharmacia Ab Monoclonal antibody
US6500660B1 (en) * 1996-11-27 2002-12-31 Université Catholique de Louvain Chimeric target molecules having a regulatable activity
ES2361267T3 (es) * 1997-04-07 2011-06-15 Genentech Inc. Procedimiento para la produccion de anticuerpos humanizados mediante mutagénesis aleatoria.
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
JP3957765B2 (ja) 1997-04-07 2007-08-15 ジェネンテク・インコーポレイテッド 抗ｖｅｇｆ抗体
US20070059302A1 (en) * 1997-04-07 2007-03-15 Genentech, Inc. Anti-vegf antibodies
US20020032315A1 (en) * 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
US6306826B1 (en) 1997-06-04 2001-10-23 The Regents Of The University Of California Treatment of heart failure with growth hormone
US6639050B1 (en) 1997-07-21 2003-10-28 Ohio University Synthetic genes for plant gums and other hydroxyproline-rich glycoproteins
US7378506B2 (en) 1997-07-21 2008-05-27 Ohio University Synthetic genes for plant gums and other hydroxyproline-rich glycoproteins
GB9723955D0 (en) 1997-11-14 1998-01-07 Generic Biolog Limited Improvements in or relating to detection of molecules in samples
GB2375765B (en) * 1997-11-14 2003-02-26 Kymed Gb Ltd Tagged growth hormone molecules
US6274712B1 (en) * 1997-12-23 2001-08-14 3-Dimensional Pharmaceuticals, Inc. Analogs of human basic fibroblast growth factor mutated at one or more of the positions glutamute 89, aspartate 101 or leucine 137
AU5122499A (en) 1998-07-27 2000-02-21 Genentech Inc. Improved transformation efficiency in phage display through modification of a coat protein
EP1127944B9 (de) * 1998-10-21 2009-08-12 Chugai Seiyaku Kabushiki Kaisha Verfahren zum screenen von verbindungen, die die produktion von entzündungszytokinen inhibieren
AU776672B2 (en) 1998-12-30 2004-09-16 Beth Israel Deaconess Medical Center Characterization of a calcium channel family
US7063959B1 (en) * 1998-12-30 2006-06-20 Beth Israel Deaconess Medical Center, Inc. Compositions of the SOC/CRAC calcium channel protein family
US20040005673A1 (en) 2001-06-29 2004-01-08 Kevin Jarrell System for manipulating nucleic acids
ATE439437T1 (de) * 1999-01-05 2009-08-15 Univ Boston Verbessertes klonierungsverfahren
EP1171601B1 (de) 1999-04-26 2006-10-18 Beth Israel Deaconess Medical Center, Inc. Nukleinsäure, die für polypeptide kodieren die eine mutt-domäne enthalten
US6946265B1 (en) * 1999-05-12 2005-09-20 Xencor, Inc. Nucleic acids and proteins with growth hormone activity
US7166573B1 (en) * 1999-05-28 2007-01-23 Ludwig Institute For Cancer Research Breast, gastric and prostate cancer associated antigens and uses therefor
JP2003527826A (ja) 1999-06-30 2003-09-24 ルードヴィッヒ インスティテュート フォー キャンサー リサーチ 癌関連抗原およびその使用
AT408721B (de) 1999-10-01 2002-02-25 Cistem Biotechnologies Gmbh Pharmazeutische zusammensetzung enthaltend ein antigen
WO2001044463A1 (en) * 1999-12-15 2001-06-21 Genentech, Inc. Shotgun scanning, a combinatorial method for mapping functional protein epitopes
SE0000837D0 (sv) 2000-03-13 2000-03-13 Pharmacia & Upjohn Ab New use
DE10016083A1 (de) * 2000-03-31 2001-10-18 Ingenium Pharmaceuticals Ag Nicht-menschliches Tiermodell für Wachstumsdefizienz und Defekte der Informationsverarbeitung oder der kognitiven Funktion und seine Verwendung
US20020032154A1 (en) * 2000-06-07 2002-03-14 Peyman John A. Interferon-suppressing placental lactogen peptides
US7435562B2 (en) * 2000-07-21 2008-10-14 Modular Genetics, Inc. Modular vector systems
AU2001277014A1 (en) * 2000-07-21 2002-02-05 Trustees Of Boston University Modular vector systems
JP4520631B2 (ja) * 2000-11-22 2010-08-11 松本油脂製薬株式会社 耐久透水性付与剤及びその繊維
US7271150B2 (en) 2001-05-14 2007-09-18 United States Of America, Represented By The Secretary, Department Of Health And Human Services Modified growth hormone
US20030087274A1 (en) * 2001-07-05 2003-05-08 Anderson David W. Therapeutic polypeptides, nucleic acids encoding same, and methods of use
CA2458261A1 (en) * 2001-08-30 2003-03-06 Stem Cell Therapeutics Inc. Differentiation of neural stem cells and therapeutic use thereof
AU2002325711C1 (en) 2001-09-14 2008-05-29 Stem Cell Therapeutics Inc. Prolactin induced increase in neutral stem cell numbers and therapeutical use thereof
US20030054551A1 (en) * 2001-09-18 2003-03-20 Stem Cell Therapeutics Inc. Effect of growth hormone and IGF-1 on neural stem cells
ES2545090T3 (es) 2001-12-21 2015-09-08 Human Genome Sciences, Inc. Proteínas de fusión de albúmina y GCSF
ES2685697T3 (es) 2002-05-09 2018-10-10 The Brigham And Women's Hospital, Inc. 1L1RL-1 como un marcador de enfermedades cardiovasculares
AU2003239966B9 (en) * 2002-06-03 2010-08-26 Genentech, Inc. Synthetic antibody phage libraries
WO2004011632A2 (en) * 2002-07-30 2004-02-05 Stem Cell Therapeutics Inc. Oligodendrocyte production from multipotent neural stem cells
WO2004011497A1 (en) * 2002-07-31 2004-02-05 Stem Cell Therapeutics Inc. Method of enhancing neural stem cell proliferation, differentiation, and survival using pituitary adenylate cyclase activating polypeptide (pacap)
US7611700B2 (en) * 2002-09-09 2009-11-03 Hanall Pharmaceuticals, Co., Ltd. Protease resistant modified interferon alpha polypeptides
ATE537186T1 (de) 2002-10-07 2011-12-15 Ludwig Inst For Cancer Res Ltd P53-bindendes polypeptid
WO2004065416A2 (en) * 2003-01-16 2004-08-05 Genentech, Inc. Synthetic antibody phage libraries
US7396646B2 (en) * 2003-01-22 2008-07-08 Modular Genetics, Inc. Alien sequences
WO2004064482A2 (en) * 2003-01-22 2004-08-05 Modular Genetics, Inc. Alien sequences
NZ603330A (en) 2003-02-11 2015-02-27 Shire Human Genetic Therapies Diagnosis and treatment of multiple sulfatase deficiency and other sulfatase deficiencies
US8071645B2 (en) 2003-06-12 2011-12-06 The Regents Of The University Of Colorado Systems and methods for treating human inflammatory and proliferative diseases and wounds, with fatty acid metabolism inhibitors and/or glycolytic inhibitors
JP2007501011A (ja) * 2003-08-01 2007-01-25 ジェネンテック・インコーポレーテッド 制限多様性配列を有する結合型ポリペプチド
US20060026719A1 (en) 2004-01-14 2006-02-02 Kieliszewski Marcia J Methods of producing peptides/proteins in plants and peptides/proteins produced thereby
ES2642214T3 (es) 2004-01-21 2017-11-15 Novo Nordisk Health Care Ag Conjugación de péptidos mediante transglutaminasa
NZ586034A (en) 2004-02-02 2011-10-28 Ambrx Inc Modified human growth hormone polypeptides and their uses
ATE556716T1 (de) * 2004-02-13 2012-05-15 Stem Cell Therapeutics Corp Verwendung des luteinisierenden hormons (lh) und von choriongonadotrophin (hcg) für die proliferation von neuralen stammzellen und neurogenese
US7785903B2 (en) * 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
WO2005118621A2 (en) * 2004-04-16 2005-12-15 Genentech, Inc. Omi pdz modulators
WO2005110015A2 (en) 2004-04-19 2005-11-24 Ohio University Cross-linkable glycoproteins and methods of making the same
AU2005250369A1 (en) * 2004-05-18 2005-12-15 Genentech, Inc. M13 virus major coat protein variants for C-terminal and BI-terminal display of a heterologous protein
US7632924B2 (en) 2004-06-18 2009-12-15 Ambrx, Inc. Antigen-binding polypeptides and their uses
AU2004320986A1 (en) * 2004-06-23 2006-01-05 Usv Limited Chimeric human growth hormone derived from the placenta and pituitary isoform and processes for obtaining said chimera
BRPI0512396A (pt) 2004-07-21 2008-03-11 Ambrx Inc polipeptìdeos biossintéticos utilizando aminoácidos codificados não naturalmente
US7998930B2 (en) 2004-11-04 2011-08-16 Hanall Biopharma Co., Ltd. Modified growth hormones
US8197817B2 (en) 2004-12-17 2012-06-12 Dana-Farber Cancer Institute, Inc. Regulation of mink in thymocytes and T lymphocytes
CA2594557C (en) * 2004-12-22 2016-04-26 Ambrx, Inc. Modified human growth hormone
KR101224781B1 (ko) * 2004-12-22 2013-01-21 암브룩스, 인코포레이티드 비천연적으로 코딩된 아미노산을 포함하는 인간 성장호르몬의 조제물
JP2008525032A (ja) 2004-12-22 2008-07-17 アンブレツクス・インコーポレイテツド 組換えヒト成長ホルモンを発現及び精製するための方法
US7736872B2 (en) 2004-12-22 2010-06-15 Ambrx, Inc. Compositions of aminoacyl-TRNA synthetase and uses thereof
JP2008541769A (ja) * 2005-06-03 2008-11-27 アンブレツクス・インコーポレイテツド 改善されたヒトインターフェロン分子及びそれらの使用
WO2007094842A2 (en) 2005-12-02 2007-08-23 Genentech, Inc. Binding polypeptides and uses thereof
JP4829969B2 (ja) * 2005-08-18 2011-12-07 アンブルックス，インコーポレイテッド ｔＲＮＡ組成物、およびその使用
EP1928488A4 (de) * 2005-09-27 2009-07-22 Stem Cell Therapeutics Corp Regulierung der oligodendrozyten-vorläufer-zellproliferation mit prolactin
EP1934610B1 (de) * 2005-10-12 2010-01-27 Allergan, Inc. Tests der molekularen oder subzellulären interaktivität unter verwendung von depolarisierung nach resonanzenergietransfer (daret)
WO2007056441A2 (en) 2005-11-07 2007-05-18 Genentech, Inc. Binding polypeptides with diversified and consensus vh/vl hypervariable sequences
WO2007056448A2 (en) * 2005-11-08 2007-05-18 Ambrx, Inc. Accelerants for the modification of non-natural amino acids and non-natural amino acid polypeptides
CN101454461A (zh) * 2005-11-16 2009-06-10 Ambrx公司 包括非天然氨基酸的方法和组合物
JP2009519942A (ja) * 2005-12-14 2009-05-21 アンブルックス，インコーポレイテッド 非天然アミノ酸およびポリペプチドを含んでいる組成物、それらに関する方法、ならびに、それらの使用
JP2009530234A (ja) * 2006-03-17 2009-08-27 ステム セル セラピューティクス コーポレイション 神経変性疾患の治療のためのｌｈまたはｈｃｇ、およびｅｐｏについての投与レジメン
US7695928B2 (en) 2006-04-10 2010-04-13 Genentech, Inc. Disheveled PDZ modulators
AU2007249408A1 (en) * 2006-05-09 2007-11-22 Genentech, Inc. Binding polypeptides with optimized scaffolds
EP2826788B1 (de) 2006-06-21 2017-12-13 MUSC Foundation for Research Development Targeting des komplement-faktors h zur krankheitsbehandlung mit cr2-fh molekulen
DK2061878T3 (da) * 2006-09-08 2014-04-07 Ambrx Inc Hybridsuppressor-trna for hvirveldyrceller
JP5840345B2 (ja) * 2006-09-08 2016-01-06 アンブルックス, インコーポレイテッドAmbrx, Inc. 修飾ヒト血漿ポリペプチドまたは修飾ヒトＦｃ足場タンパク質ならびにこれらの利用
MX2009002526A (es) * 2006-09-08 2009-04-16 Ambrx Inc Transcripcion de tarn supresor en celulas de vertebrados.
US20100022454A1 (en) * 2006-10-03 2010-01-28 Novo Nordisk A/S Peptides with High Affinity for the Prolactin Receptor
JP4842400B2 (ja) 2007-03-22 2011-12-21 ヘプテアズ・セラピューティクス・リミテッド Ｇタンパク質共役型受容体変異体及びその選択方法
KR101476472B1 (ko) * 2007-03-30 2015-01-05 암브룩스, 인코포레이티드 변형된 ｆｇｆ-21 폴리펩티드 및 그 용도
NZ580686A (en) 2007-05-02 2012-11-30 Ambrx Inc Modified interferon beta polypeptides and their uses
WO2008143666A2 (en) 2007-05-17 2008-11-27 Genentech, Inc. Crystal structures of neuropilin fragments and neuropilin-antibody complexes
AU2008326324B9 (en) * 2007-11-20 2012-11-15 Ambrx, Inc. Modified insulin polypeptides and their uses
GB0724051D0 (en) 2007-12-08 2008-01-16 Medical Res Council Mutant proteins and methods for producing them
GB0724860D0 (en) 2007-12-20 2008-01-30 Heptares Therapeutics Ltd Screening
US9938333B2 (en) 2008-02-08 2018-04-10 Ambrx, Inc. Modified leptin polypeptides and their uses
GB0802474D0 (en) 2008-02-11 2008-03-19 Heptares Therapeutics Ltd Mutant proteins and methods for selecting them
ES2963062T3 (es) * 2008-07-23 2024-03-25 Ambrx Inc Polipéptidos G-CSF bovinos modificados y sus usos
KR20110039348A (ko) 2008-08-06 2011-04-15 노보 노르디스크 헬스 케어 악티엔게젤샤프트 연장된 생체내 효능을 가지는 콘쥬게이트된 단백질
US8937046B2 (en) 2008-09-22 2015-01-20 The Regents Of The University Of Colorado, A Body Corporate Modulating the alternative complement pathway
NZ592249A (en) 2008-09-26 2013-03-28 Ambrx Inc Non-natural amino acid replication-dependent microorganisms and vaccines
BRPI0919403A2 (pt) * 2008-09-26 2017-09-26 Ambrx Inc polipeptídeos modificados de eritropoetina animal e seus usos
KR20110122100A (ko) 2009-01-22 2011-11-09 노보 노르디스크 헬스 케어 악티엔게젤샤프트 안정한 성장 호르몬 화합물
JP5647222B2 (ja) 2009-04-10 2014-12-24 アブリンクス エン．ヴェー． Ｉｌ−６ｒ関連疾患及び障害の治療のためのｉｌ−６ｒに指向性を有する改善されたアミノ酸配列及びこれを含むポリペプチド
US8945567B2 (en) 2009-06-05 2015-02-03 Ablynx N.V. Monovalent, bivalent and trivalent anti human respiratory syncytial virus (HRSV) nanobody constructs for the prevention and/or treatment of respiratory tract infections
GB0910725D0 (en) 2009-06-22 2009-08-05 Heptares Therapeutics Ltd Mutant proteins and methods for producing them
EP2461831B1 (de) 2009-08-06 2018-11-21 Novo Nordisk Health Care AG Wachstumshormone mit verlängerter in-vivo-wirksamkeit
EP2507262A1 (de) 2009-11-30 2012-10-10 Ablynx N.V. Verbesserte gegen hrsv gerichtete aminosäuresequenzen und polypeptide damit zur prävention und/oder behandlung von atemwegsinfektionen
CN107674121A (zh) 2009-12-21 2018-02-09 Ambrx 公司 经过修饰的牛促生长素多肽和其用途
CN104017063A (zh) 2009-12-21 2014-09-03 Ambrx公司 经过修饰的猪促生长素多肽和其用途
JP5980689B2 (ja) 2010-01-22 2016-08-31 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー 安定な成長ホルモン化合物
CN102834109B (zh) 2010-01-22 2016-01-20 诺沃—诺迪斯克保健股份有限公司 稳定的生长激素化合物
EP2595661A1 (de) 2010-07-22 2013-05-29 Novo Nordisk Health Care AG Wachstumshormonkonjugate
EP2605789B1 (de) 2010-08-17 2019-06-05 Ambrx, Inc. Modifizierte relaxinpolypeptide und ihre verwendungen
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
AR083006A1 (es) 2010-09-23 2013-01-23 Lilly Co Eli Formulaciones para el factor estimulante de colonias de granulocitos (g-csf) bovino y variantes de las mismas
EP2446898A1 (de) 2010-09-30 2012-05-02 Laboratorios Del. Dr. Esteve, S.A. Verwendung von Wachstumshormonen zur Verbesserung der Immunantwort bei immunsupprimierten Patienten
JP6190813B2 (ja) 2011-10-14 2017-08-30 ジェネンテック， インコーポレイテッド チモーゲン活性化因子
CN103974709B (zh) 2011-10-14 2016-12-14 霍夫曼-拉罗奇有限公司 Bace1的肽抑制剂
WO2014087010A1 (en) 2012-12-07 2014-06-12 Ablynx N.V. IMPROVED POLYPEPTIDES DIRECTED AGAINST IgE
JP6464145B2 (ja) 2013-04-05 2019-02-06 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー 成長ホルモン化合物製剤
JP2016523241A (ja) 2013-06-14 2016-08-08 プレジデント アンド フェローズ オブ ハーバード カレッジ 安定化されたポリペプチドインスリン受容体調節剤
KR20240024362A (ko) 2014-10-24 2024-02-23 브리스톨-마이어스 스큅 컴퍼니 변형된 fgf-21 폴리펩티드 및 그의 용도
US20190382439A1 (en) * 2015-11-16 2019-12-19 Ubiprotein, Corp. Method for extending half-life of a protein
US11007254B2 (en) 2016-10-17 2021-05-18 Musc Foundation For Research Development Compositions and methods for treating central nervous system injury
MX2019008449A (es) 2017-02-08 2019-09-09 Bristol Myers Squibb Co Polipetidos de relaxina modificada que comprenden un mejorador farmacocinetico y sus usos.

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4665160A (en) 1982-03-22 1987-05-12 Genentech, Inc. Novel human growth hormone like protein HGH-V encoded in the human genome
US4670393A (en) * 1982-03-22 1987-06-02 Genentech, Inc. DNA vectors encoding a novel human growth hormone-variant protein
US4446235A (en) * 1982-03-22 1984-05-01 Genentech, Inc. Method for cloning human growth hormone varient genes
US4699897A (en) * 1983-06-04 1987-10-13 Amgen Biologically active peptides structurally related to regions within growth hormones
BG49718A3 (en) 1983-07-15 1992-01-15 Bio Technology General Corp Method for preparing of polypeptid with superoxiddismutasne activitty
US4888286A (en) * 1984-02-06 1989-12-19 Creative Biomolecules, Inc. Production of gene and protein analogs through synthetic gene design using double stranded synthetic oligonucleotides
US4732973A (en) * 1984-06-14 1988-03-22 Chiron Corporation Active site modified protease α-1-antitrypsin inhibitors
US4665180A (en) * 1984-11-06 1987-05-12 Petrolite Corporation Substituted tetrahydropyrimidines and octahydrophenanthridines
US4655160A (en) * 1985-09-10 1987-04-07 David R. Ligh Deck box
AU615194B2 (en) * 1987-03-12 1991-09-26 Amgen, Inc. Bovine growth hormone analogs
WO1988007578A1 (en) * 1987-04-02 1988-10-06 Genentech, Inc. Substrate assisted catalysis
US5204244A (en) * 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
GB8727489D0 (en) * 1987-11-24 1987-12-23 Connaught Lab Detoxification of pertussis toxin
CA1323293C (en) 1987-12-11 1993-10-19 Keith C. Backman Assay using template-dependent nucleic acid probe reorganization
WO1990004788A1 (en) * 1988-10-28 1990-05-03 Genentech, Inc. Method for identifying active domains and amino acid residues in polypeptides and hormone variants
US5350836A (en) 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
DE69712124T2 (de) 1996-02-13 2002-12-12 Jcr Pharmaceutical Co Hormones de croissance humaines mutantes et leur utilisation

Also Published As

Publication number Publication date
EP0397834B1 (de) 2000-02-02
WO1990004788A1 (en) 1990-05-03
US6428954B1 (en) 2002-08-06
US6451561B1 (en) 2002-09-17
EP0397834A4 (en) 1992-10-28
CA2001774A1 (en) 1990-04-28
DE68929151D1 (de) 2000-03-09
US5580723A (en) 1996-12-03
CA2001774C (en) 2001-10-16
ATE189526T1 (de) 2000-02-15
US5955346A (en) 1999-09-21
EP0397834A1 (de) 1990-11-22
CA2345497A1 (en) 1990-04-28

Similar Documents

Publication Publication Date Title
DE68929151D1 (de) Verfahren zum nachweis von aktiven domänen und aminosäureresten in polypeptiden und hormonvarianten
Schally et al. The amino acid sequence of a peptide with growth hormone-releasing activity isolated from porcine hypothalamus
Mobley et al. Characterization and isolation of proteolytically modified nerve growth factor
LU91015I2 (fr) Recombinate (Rurioctocog alfa) dans toutes ses formes couvertes par le brevet de base
Hofmann et al. An approach to the targeted attachment of peptides and proteins to solid supports.
DE68905633D1 (de) Markierer der t-zelle aktivierung.
Eipper et al. Amidation of joining peptide, a major pro-ACTH/endorphin-derived product peptide.
ES2090598T3 (es) Procedimiento de ensayo de proteinas de union de hormonas inmunofuncional mediado por ligando.
DE68913016D1 (de) Verfahren und Zelle zur Gefrierprüfung von Proben geologischer Schichten.
ATE318902T1 (de) Allergene proteine und peptide von hundhautanhangsgebilden und ihre verwendung
Sexton et al. Biologically active salmon calcitonin-like peptide is present in rat brain
Schwyzer Synthetische polypeptide mit physiologischer wirkung
Vestling Insulin: HPLC mapping of protease digestion products: A biochemistry laboratory experiment
IT1242173B (it) Metodo di analisi quantitativa altamente sensibile di acidi biliari e composizione per la analisi quantitativa.
Nakagawa et al. Retro analogs related to oxytocin
DE3783840T2 (de) Verfahren zur bestimmung von plasma-protein und testsatz dafuer.
Gargan et al. 206 The generation of a fibrin specific monoclonal antibody using a unique “antigen-free” animal system

Legal Events

Date Code Title Description
8364 No opposition during term of opposition